Asset
ULODESINE
BioCryst Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01129648 | phase2 | completed | 2010-05-01 | 2010-11-01 | BioCryst Pharmaceuticals | Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout |
| NCT00985127 | phase2 | completed | 2009-09-01 | 2010-09-01 | BioCryst Pharmaceuticals | Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout |
FDA applications (0)
This company has no applications containing this asset.